GlobeNewswire

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
20/04/2026
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM [...]
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
20/04/2026
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd . (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced [...]
Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026
20/04/2026
TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. [...]
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
20/04/2026
Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preserved Identification of potential [...]
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
20/04/2026
James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children’s Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET WAYNE, Pa., April 20, 2026 (GLOBE [...]
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
20/04/2026
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed antibody with [...]
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
20/04/2026
Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care 1 Haemoglobin response was superior with etavopivat: 48.7% of people [...]
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
20/04/2026
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026 A non-invasive topical [...]
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
20/04/2026
Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026 A non-invasive topical treatment for diabetic macular edema (DME) has the [...]
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
20/04/2026
This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, [...]
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
20/04/2026
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies related to rapid liver clearance Pre-treatment with [...]
Nanobiotix annonce de nouvelles données précliniques démontrant une amélioration de la biodisponibilité systémique et la réduction de la toxicité pour des immunothérapies à ADN delivrées par LNP après traitement avec sa technologie de nanoprimer
20/04/2026
Une étude préclinique chez la souris a évalué le potentiel de la technologie nanoprimer à surmonter les barrières courantes rencontrées par les thérapies délivrées par nanoparticules lipidiques (« LNP »), qui sont [...]
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
20/04/2026
Press Release Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026 April 20, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an [...]
Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026
20/04/2026
Communiqué de presse Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026 20 avril 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA ( [...]
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
20/04/2026
ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the [...]
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
20/04/2026
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent [...]
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
20/04/2026
WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
20/04/2026
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure [...]
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
20/04/2026
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum